Abstract
The prognosis of small-cell lung cancer remains poor and it is speculated that small-cell lung cancer patients with end-stage renal failure undergoing hemodialysis have a poorer prognosis. In this article, we present a Japanese woman with extensive small-cell lung cancer with end-stage renal failure undergoing hemodialysis who received multiple courses of chemotherapy. Although she achieved long-term survival of more than 2 years, the last-line chemotherapy, consisting of irinotecan, induced grade 4 febrile neutropenia and her performance status deteriorated even with a reduced dose according to the analysis of UDP-glucuronosyltransferase 1A1. We also conducted a pharmacokinetic analysis of irinotecan, the resulting values of which were much higher than in previous reports. Although further studies are needed, chemotherapy for small-cell lung cancer patients should not be withheld just because they are undergoing hemodialysis; however, chemotherapy should be performed more carefully because more severe toxicities can occur than expected.
Original language | English |
---|---|
Article number | hyq244 |
Pages (from-to) | 582-585 |
Number of pages | 4 |
Journal | Japanese journal of clinical oncology |
Volume | 41 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2011 |
Externally published | Yes |
Keywords
- Hemodialysis
- Irinotecan
- Multiple courses chemotherapy
- Pharmacokinetics
- Small-cell lung cancer
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research